New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
David Brown, Global Head of Epidemiology, summarizes the three FDA guidances related to data sources, data standards, and regulatory considerations in RWE/RWD and benefits of early engagement.
Learn More